The unusual investment strategy that's returned more than 30% this year

Plus, your morning report takes a look at three companies on brokers' radars.
The Morning Wrap

Livewire Markets


Note: us markets are closed today because of the Thanksgiving holiday.



Today's calendar is fairly quiet. Only New Zealand retail sales for the third quarter are out today, and that's interesting purely as a forward indicator for whether inflation could come down anytime soon. 

Next week, it's all eyes on US jobs data and the latest round of OPEC+ meetings. And while we'll tell you more about that on Monday, I thought it'd be worth sharing with you this chart from FactSet through the Wall Street Journal. The divergence between New York Crude Oil prices and the S&P 500 Energy Index is starting to show. 

And the divergence is also showing in Australia. While the ASX Energy Index is up nearly 50% year-on-year, Brent Crude prices have come off markedly.

Source: Trading View
Source: Trading View


For our chart today, I've called on the work of Charlie Bilello, who published this interesting chart on what would have happened had you traded the S&P 500 index this year. The twist is that the trading strategy channels a little Warren Buffett: buy when the VIX is over 30 and sell when it's less than 20. 

If you followed that strategy to the letter, you'd now be up 27% year-to-date. Had you done the inverse (i.e. buy during calm or periods of low volatility, and sell during the panic), you'd actually be down 33%.

So I guess it does pay to be a contrarian!


FinTwit is still obsessed over this FTX drama, but even you couldn't write this script. Yes, that is the now-bankrupt founder of FTX being described as a "philanthropist". 
FinTwit is still obsessed over this FTX drama, but even you couldn't write this script. Yes, that is the now-bankrupt founder of FTX being described as a "philanthropist". 


Today's stocks to watch have all made new announcements this week. In each case, we've also picked out situations where a broker has raised the price target or made rating changes. 

Macquarie has boosted the price target on CSL (ASX: CSL) by $13.50, following US FDA approval for the company's haemophilia gene therapy. The broker thinks there could be as much as an extra 6% added to earnings by the end of the decade as a result.

Credit Suisse, Macquarie, and Ord Minnett have all raised their price targets on Qantas (ASX: QAN) following its earnings guidance upgrade earlier this week. 

And after Smartgroup (ASX: SIQ) downgraded its earnings guidance earlier this week due to supply chain constraints, Macquarie has downgraded the company to a NEUTRAL from outperform, with a new price target of $4.75/share.

Hans Lee wrote today's report. Chris Conway is away today.


If you've enjoyed this edition, hit follow on this profile to know when we post new content and click the like button so we know what you enjoy reading.

If you have a chart and/or a stat that you would like to see featured in a future edition of the newsletter, drop us a note at

Livewire gives readers access to information and educational content provided by financial services professionals and companies (“Livewire Contributors”). Livewire does not operate under an Australian financial services licence and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any advice given. Any advice on this site is general in nature and does not take into consideration your objectives, financial situation or needs. Before making a decision please consider these and any relevant Product Disclosure Statement. Livewire has commercial relationships with some Livewire Contributors.

3 stocks mentioned

1 contributor mentioned

The Morning Wrap
Markets Wrap
Livewire Markets

Livewire and Market Index's pre-opening bell news and analysis wrap. Available weekday mornings and written by Kerry Sun.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Sign In or Join Free to comment